E
Bio-Rad Laboratories, Inc.
BIOB
$279.91
-$58.64-17.32%
E
Sell
5/8/2023Downgrade
Bio-Rad Laboratories, Inc. (BIOB) was downgraded to E+ from D on 5/8/2023 due to a significant decline in the efficiency index, total return index and valuation index. Net income declined 91.73% from $833.49M to $68.96M.
Bio-Rad Laboratories, Inc. (BIOB) was downgraded to E+ from D on 5/8/2023 due to a significant decline in the efficiency index, total return index and valuation index. Net income declined 91.73% from $833.49M to $68.96M.
D
Sell
10/10/2022Downgrade
Bio-Rad Laboratories, Inc. (BIOB) was downgraded to D from D+ on 10/10/2022 due to a noticeable decline in the efficiency index, volatility index and total return index. Total capital declined 10.98% from $11.59B to $10.31B.
Bio-Rad Laboratories, Inc. (BIOB) was downgraded to D from D+ on 10/10/2022 due to a noticeable decline in the efficiency index, volatility index and total return index. Total capital declined 10.98% from $11.59B to $10.31B.
D
Sell
6/15/2022Downgrade
Bio-Rad Laboratories, Inc. (BIOB) was downgraded to D+ from C- on 6/15/2022 due to a decline in the volatility index and total return index.
Bio-Rad Laboratories, Inc. (BIOB) was downgraded to D+ from C- on 6/15/2022 due to a decline in the volatility index and total return index.
C
Hold
4/29/2022Downgrade
Bio-Rad Laboratories, Inc. (BIOB) was downgraded to C- from C on 4/29/2022 due to a significant decline in the total return index, volatility index and solvency index.
Bio-Rad Laboratories, Inc. (BIOB) was downgraded to C- from C on 4/29/2022 due to a significant decline in the total return index, volatility index and solvency index.
C
Hold
11/7/2017Upgraded
Bio-Rad Laboratories, Inc. (BIOB) was upgraded to C from C- on 11/7/2017 due to an increase in the total return index and volatility index.
Bio-Rad Laboratories, Inc. (BIOB) was upgraded to C from C- on 11/7/2017 due to an increase in the total return index and volatility index.
C
Hold
10/23/2017Downgrade
Bio-Rad Laboratories, Inc. (BIOB) was downgraded to C- from C on 10/23/2017 due to a major decline in the total return index.
Bio-Rad Laboratories, Inc. (BIOB) was downgraded to C- from C on 10/23/2017 due to a major decline in the total return index.
C
Hold
9/29/2017Upgraded
Bio-Rad Laboratories, Inc. (BIOB) was upgraded to C from C- on 9/29/2017 due to a major increase in the total return index and volatility index.
Bio-Rad Laboratories, Inc. (BIOB) was upgraded to C from C- on 9/29/2017 due to a major increase in the total return index and volatility index.
C
Hold
9/14/2017Downgrade
Bio-Rad Laboratories, Inc. (BIOB) was downgraded to C- from C on 9/14/2017 due to a significant decline in the valuation index, efficiency index and growth index. EBIT declined 108.99% from $26.16M to -$2.35M, net income declined 59.44% from $12.41M to $5.04M, and earnings per share declined from $0.41 to $0.17.
Bio-Rad Laboratories, Inc. (BIOB) was downgraded to C- from C on 9/14/2017 due to a significant decline in the valuation index, efficiency index and growth index. EBIT declined 108.99% from $26.16M to -$2.35M, net income declined 59.44% from $12.41M to $5.04M, and earnings per share declined from $0.41 to $0.17.
C
Hold
3/11/2016Downgrade
Bio-Rad Laboratories, Inc. (BIOB) was downgraded to C from C+ on 3/11/2016 due to a decline in the volatility index, total return index and solvency index.
Bio-Rad Laboratories, Inc. (BIOB) was downgraded to C from C+ on 3/11/2016 due to a decline in the volatility index, total return index and solvency index.
C
Hold
11/6/2015Downgrade
Bio-Rad Laboratories, Inc. (BIOB) was downgraded to C+ from B- on 11/6/2015 due to a substantial decline in the growth index, total return index and volatility index. Earnings per share declined from $0.97 to $0.59, EBIT declined 27.24% from $43.81M to $31.87M, and total revenue declined 7.14% from $506.1M to $469.96M.
Bio-Rad Laboratories, Inc. (BIOB) was downgraded to C+ from B- on 11/6/2015 due to a substantial decline in the growth index, total return index and volatility index. Earnings per share declined from $0.97 to $0.59, EBIT declined 27.24% from $43.81M to $31.87M, and total revenue declined 7.14% from $506.1M to $469.96M.
B
Buy
10/12/2015Downgrade
Bio-Rad Laboratories, Inc. (BIOB) was downgraded to B- from B on 10/12/2015 due to a major decline in the volatility index, total return index and efficiency index.
Bio-Rad Laboratories, Inc. (BIOB) was downgraded to B- from B on 10/12/2015 due to a major decline in the volatility index, total return index and efficiency index.
B
Buy
7/20/2015Upgraded
Bio-Rad Laboratories, Inc. (BIOB) was upgraded to B from B- on 7/20/2015 due to an increase in the total return index.
Bio-Rad Laboratories, Inc. (BIOB) was upgraded to B from B- on 7/20/2015 due to an increase in the total return index.
B
Buy
7/1/2015Downgrade
Bio-Rad Laboratories, Inc. (BIOB) was downgraded to B- from B on 7/1/2015 due to a major decline in the growth index and solvency index. Earnings per share declined from $1.3394 to $0.61, EBIT declined 46.3% from $63.96M to $34.35M, and operating cash flow declined 26.78% from $40.22M to $29.45M.
Bio-Rad Laboratories, Inc. (BIOB) was downgraded to B- from B on 7/1/2015 due to a major decline in the growth index and solvency index. Earnings per share declined from $1.3394 to $0.61, EBIT declined 46.3% from $63.96M to $34.35M, and operating cash flow declined 26.78% from $40.22M to $29.45M.
B
Buy
4/6/2015Upgraded
Bio-Rad Laboratories, Inc. (BIOB) was upgraded to B from B- on 4/6/2015 due to a large increase in the volatility index, solvency index and total return index.
Bio-Rad Laboratories, Inc. (BIOB) was upgraded to B from B- on 4/6/2015 due to a large increase in the volatility index, solvency index and total return index.
B
Buy
3/5/2015Upgraded
Bio-Rad Laboratories, Inc. (BIOB) was upgraded to B- from C+ on 3/5/2015 due to a substantial increase in the growth index, valuation index and solvency index. Earnings per share increased from $0.39 to $1.3394, EBIT increased 120.78% from $30.24M to $66.76M, and the quick ratio increased from 2.1 to 2.41.
Bio-Rad Laboratories, Inc. (BIOB) was upgraded to B- from C+ on 3/5/2015 due to a substantial increase in the growth index, valuation index and solvency index. Earnings per share increased from $0.39 to $1.3394, EBIT increased 120.78% from $30.24M to $66.76M, and the quick ratio increased from 2.1 to 2.41.
C
Hold
3/2/2015Upgraded
Bio-Rad Laboratories, Inc. (BIOB) was upgraded to C+ from C on 3/2/2015 due to an increase in the valuation index, efficiency index and growth index. Operating cash flow increased 2.93% from $80.9M to $83.27M.
Bio-Rad Laboratories, Inc. (BIOB) was upgraded to C+ from C on 3/2/2015 due to an increase in the valuation index, efficiency index and growth index. Operating cash flow increased 2.93% from $80.9M to $83.27M.
C
Hold
5/19/2014Downgrade
Bio-Rad Laboratories, Inc. (BIOB) was downgraded to C from C+ on 5/19/2014 due to a noticeable decline in the growth index, volatility index and valuation index. Earnings per share declined from $1.0391 to $0.23, EBIT declined 65.57% from $59.46M to $20.47M, and total revenue declined 15.48% from $602.64M to $509.34M.
Bio-Rad Laboratories, Inc. (BIOB) was downgraded to C from C+ on 5/19/2014 due to a noticeable decline in the growth index, volatility index and valuation index. Earnings per share declined from $1.0391 to $0.23, EBIT declined 65.57% from $59.46M to $20.47M, and total revenue declined 15.48% from $602.64M to $509.34M.
C
Hold
5/8/2014Downgrade
Bio-Rad Laboratories, Inc. (BIOB) was downgraded to C+ from B- on 5/8/2014 due to a decline in the total return index and volatility index.
Bio-Rad Laboratories, Inc. (BIOB) was downgraded to C+ from B- on 5/8/2014 due to a decline in the total return index and volatility index.
B
Buy
3/21/2014Upgraded
Bio-Rad Laboratories, Inc. (BIOB) was upgraded to B- from C+ on 3/21/2014 due to a substantial increase in the volatility index, growth index and solvency index. EBIT increased 109.69% from $28.36M to $59.46M, total revenue increased 19.32% from $505.07M to $602.64M, and operating cash flow increased 16.86% from $62.85M to $73.44M.
Bio-Rad Laboratories, Inc. (BIOB) was upgraded to B- from C+ on 3/21/2014 due to a substantial increase in the volatility index, growth index and solvency index. EBIT increased 109.69% from $28.36M to $59.46M, total revenue increased 19.32% from $505.07M to $602.64M, and operating cash flow increased 16.86% from $62.85M to $73.44M.
NYSE
04/18/2024 3:59PM Eastern
Quotes delayed
